Survodutide for liver diseases

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Also followed for narrower conditions: Non-alcoholic Fatty Liver Disease

Why this status

  1. 25 Mar 2022: Trial registered, NCT05296733
  2. 27 Apr 2022: Trial started, NCT05296733

The trials

NCT05296733: A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906

State
Completed
Phase
Phase 1
People
82 taking part
Started
27 Apr 2022
Primary completion
29 Dec 2023
Arms
Part A: BI 456906: Cohort 1, Part A: BI 456906: Cohort 2, Part A: BI 456906: Cohort 3, Part A: BI 456906: Cohort 4, Part B: BI456906: Cohort 1, Part B: BI456906: Cohort 2, Part B: BI456906: Cohort 3
Results
None posted
Papers
doi:10.1016/j.jhep.2024.06.003
  1. 25 Mar 2022: Trial registered
  2. 27 Apr 2022: Trial started
  3. 29 Dec 2023: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Also known as BI 456906, Survodutide formulation A, Survodutide formulation B2.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.